Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

InfaCare Pharmaceutical

Request full access

Engaged in the development of pharmaceuticals for the neonatal and pediatric patient population

Upper Merion Township, United StatesFounded 2005Biotech & Life Sciences

About InfaCare Pharmaceutical

InfaCare Pharmaceutical Corporation was a specialty pharmaceutical company focused on developing and commercializing products for the neonatal and pediatric population. Founded in 2001 by Robert Vukovich, the Pennsylvania-based firm directed its efforts towards addressing unmet medical needs in newborns. The company's operations were centered around its lead drug candidate, stannsoporfin, a first-in-class heme oxygenase inhibitor.

The core of InfaCare's business was the clinical development of stannsoporfin (brand name Stanate) for the treatment of neonatal hyperbilirubinemia, commonly known as infant jaundice. This condition, resulting from high levels of bilirubin, can lead to severe neurological damage if not effectively managed. Stannsoporfin's mechanism of action involves inhibiting the production of bilirubin, offering a preventative pharmacological approach rather than treatments like phototherapy or exchange transfusions, which only address the issue after bilirubin levels have already risen. The product was designed to be administered as a single intramuscular injection to newborns at risk, potentially reducing the need for more invasive procedures.

Throughout its history, InfaCare was a venture-capital-backed entity, raising a total of $78.2 million over 14 funding rounds from investors including Longitude Capital, Healthcare Ventures, and Atlas Venture. A significant milestone was the completion of its Phase IIB clinical trial for stannsoporfin in 2016, after which the company reached an agreement with the U.S. Food and Drug Administration (FDA) to file a New Drug Application (NDA) based on the existing data.

In August 2017, Mallinckrodt plc entered into an agreement to acquire InfaCare, a deal that was finalized in September 2017. The transaction involved an upfront payment of $80 million, with up to $345 million in potential future payments contingent on regulatory and sales milestones. However, the development of stannsoporfin faced a major setback in May 2018 when an FDA advisory committee voted overwhelmingly against its approval, citing insufficient efficacy and safety data. This was followed by the FDA issuing a complete response letter in August 2018, formally rejecting the drug's application.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2005
Headquarters
Upper Merion Township, United States
Employees
7
Open positions
None listed
Dealroom signal
45.6/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Aug 2017 $425M — Mallinckrodt —
LATE VCOther financing Jul 2015 $12M $48M Undisclosed —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

InfaCare Pharmaceutical website traffic

Latest recorded traffic for InfaCare Pharmaceutical is 190 monthly website visits. InfaCare Pharmaceutical's team grew 40% over the past year.

Latest monthly visits190 1-year team growth+40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

InfaCare Pharmaceutical in the Upper Merion Township ecosystem

Live from Dealroom

The InfaCare Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Other known investors1 additional known investor

  • Mallinckrodt
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about InfaCare Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See InfaCare Pharmaceutical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.